Literature DB >> 27325851

Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.

Nicolas Wentzensen1, Elizabeth M Poole1, Britton Trabert1, Emily White1, Alan A Arslan1, Alpa V Patel1, V Wendy Setiawan1, Kala Visvanathan1, Elisabete Weiderpass1, Hans-Olov Adami1, Amanda Black1, Leslie Bernstein1, Louise A Brinton1, Julie Buring1, Lesley M Butler1, Saioa Chamosa1, Tess V Clendenen1, Laure Dossus1, Renee Fortner1, Susan M Gapstur1, Mia M Gaudet1, Inger T Gram1, Patricia Hartge1, Judith Hoffman-Bolton1, Annika Idahl1, Michael Jones1, Rudolf Kaaks1, Victoria Kirsh1, Woon-Puay Koh1, James V Lacey1, I-Min Lee1, Eva Lundin1, Melissa A Merritt1, N Charlotte Onland-Moret1, Ulrike Peters1, Jenny N Poynter1, Sabina Rinaldi1, Kim Robien1, Thomas Rohan1, Dale P Sandler1, Catherine Schairer1, Leo J Schouten1, Louise K Sjöholm1, Sabina Sieri1, Anthony Swerdlow1, Anna Tjonneland1, Ruth Travis1, Antonia Trichopoulou1, Piet A van den Brandt1, Lynne Wilkens1, Alicja Wolk1, Hannah P Yang1, Anne Zeleniuch-Jacquotte1, Shelley S Tworoger1.   

Abstract

PURPOSE: An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle factors by histologic subtype in the Ovarian Cancer Cohort Consortium (OC3). PATIENTS AND METHODS: Among 1.3 million women from 21 studies, 5,584 invasive epithelial ovarian cancers were identified (3,378 serous, 606 endometrioid, 331 mucinous, 269 clear cell, 1,000 other). By using competing-risks Cox proportional hazards regression stratified by study and birth year and adjusted for age, parity, and oral contraceptive use, we assessed associations for all invasive cancers by histology. Heterogeneity was evaluated by likelihood ratio test.
RESULTS: Most risk factors exhibited significant heterogeneity by histology. Higher parity was most strongly associated with endometrioid (relative risk [RR] per birth, 0.78; 95% CI, 0.74 to 0.83) and clear cell (RR, 0.68; 95% CI, 0.61 to 0.76) carcinomas (P value for heterogeneity [P-het] < .001). Similarly, age at menopause, endometriosis, and tubal ligation were only associated with endometrioid and clear cell tumors (P-het ≤ .01). Family history of breast cancer (P-het = .008) had modest heterogeneity. Smoking was associated with an increased risk of mucinous (RR per 20 pack-years, 1.26; 95% CI, 1.08 to 1.46) but a decreased risk of clear cell (RR, 0.72; 95% CI, 0.55 to 0.94) tumors (P-het = .004). Unsupervised clustering by risk factors separated endometrioid, clear cell, and low-grade serous carcinomas from high-grade serous and mucinous carcinomas.
CONCLUSION: The heterogeneous associations of risk factors with ovarian cancer subtypes emphasize the importance of conducting etiologic studies by ovarian cancer subtypes. Most established risk factors were more strongly associated with nonserous carcinomas, which demonstrate challenges for risk prediction of serous cancers, the most fatal subtype.
© 2016 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2016        PMID: 27325851      PMCID: PMC5012665          DOI: 10.1200/JCO.2016.66.8178

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  38 in total

1.  Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective.

Authors:  Elke A Jarboe; Ann K Folkins; Ronny Drapkin; Tan A Ince; Elin S Agoston; Christopher P Crum
Journal:  Histopathology       Date:  2009-11       Impact factor: 5.087

2.  Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study.

Authors:  Britton Trabert; Louise A Brinton; Garnet L Anderson; Ruth M Pfeiffer; Roni T Falk; Howard D Strickler; Sarunas Sliesoraitis; Lewis H Kuller; Margery L Gass; Barbara J Fuhrman; Xia Xu; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02-05       Impact factor: 4.254

3.  Evolving Approaches in Research and Care for Ovarian Cancers: A Report From the National Academies of Sciences, Engineering, and Medicine.

Authors:  Douglas A Levine; Beth Y Karlan; Jerome F Strauss
Journal:  JAMA       Date:  2016-05-10       Impact factor: 56.272

Review 4.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

Review 5.  Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies.

Authors:  Leo J Schouten; Christine Rivera; David J Hunter; Donna Spiegelman; Hans-Olov Adami; Alan Arslan; W Lawrence Beeson; Piet A van den Brandt; Julie E Buring; Aaron R Folsom; Gary E Fraser; Jo L Freudenheim; R Alexandra Goldbohm; Susan E Hankinson; James V Lacey; Michael Leitzmann; Annekatrin Lukanova; James R Marshall; Anthony B Miller; Alpa V Patel; Carmen Rodriguez; Thomas E Rohan; Julie A Ross; Alicja Wolk; Shumin M Zhang; Stephanie A Smith-Warner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04-01       Impact factor: 4.254

6.  Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository.

Authors:  Rayna K Matsuno; Mark E Sherman; Kala Visvanathan; Marc T Goodman; Brenda Y Hernandez; Charles F Lynch; Olga B Ioffe; David Horio; Charles Platz; Sean F Altekruse; Ruth M Pfeiffer; William F Anderson
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 8.  Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies.

Authors:  V Beral; K Gaitskell; C Hermon; K Moser; G Reeves; R Peto
Journal:  Lancet Oncol       Date:  2012-08-03       Impact factor: 41.316

9.  Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.

Authors:  Britton Trabert; Roberta B Ness; Wei-Hsuan Lo-Ciganic; Megan A Murphy; Ellen L Goode; Elizabeth M Poole; Louise A Brinton; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Galina Lurie; Susanne K Kjær; Estrid Hogdall; Allan Jensen; Daniel W Cramer; Kathryn L Terry; Allison Vitonis; Elisa V Bandera; Sara Olson; Melony G King; Urmila Chandran; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Anna H Wu; Celeste Leigh Pearce; Malcolm C Pike; Andrew Berchuck; Joellen M Schildkraut; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 11.816

10.  Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

Authors:  Ian J Jacobs; Usha Menon; Andy Ryan; Aleksandra Gentry-Maharaj; Matthew Burnell; Jatinderpal K Kalsi; Nazar N Amso; Sophia Apostolidou; Elizabeth Benjamin; Derek Cruickshank; Danielle N Crump; Susan K Davies; Anne Dawnay; Stephen Dobbs; Gwendolen Fletcher; Jeremy Ford; Keith Godfrey; Richard Gunu; Mariam Habib; Rachel Hallett; Jonathan Herod; Howard Jenkins; Chloe Karpinskyj; Simon Leeson; Sara J Lewis; William R Liston; Alberto Lopes; Tim Mould; John Murdoch; David Oram; Dustin J Rabideau; Karina Reynolds; Ian Scott; Mourad W Seif; Aarti Sharma; Naveena Singh; Julie Taylor; Fiona Warburton; Martin Widschwendter; Karin Williamson; Robert Woolas; Lesley Fallowfield; Alistair J McGuire; Stuart Campbell; Mahesh Parmar; Steven J Skates
Journal:  Lancet       Date:  2015-12-17       Impact factor: 79.321

View more
  145 in total

1.  The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.

Authors:  Citadel J Cabasag; Melina Arnold; John Butler; Manami Inoue; Britton Trabert; Penelope M Webb; Freddie Bray; Isabelle Soerjomataram
Journal:  Int J Cancer       Date:  2019-04-30       Impact factor: 7.396

2.  Targeting progesterone signaling prevents metastatic ovarian cancer.

Authors:  Olga Kim; Eun Young Park; Sun Young Kwon; Sojin Shin; Robert E Emerson; Yong-Hyun Shin; Francesco J DeMayo; John P Lydon; Donna M Coffey; Shannon M Hawkins; Lawrence A Quilliam; Dong-Joo Cheon; Facundo M Fernández; Kenneth P Nephew; Adam R Karpf; Martin Widschwendter; Anil K Sood; Robert C Bast; Andrew K Godwin; Kathy D Miller; Chi-Heum Cho; Jaeyeon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

3.  Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.

Authors:  Camilla Sköld; Tone Bjørge; Anders Ekbom; Anders Engeland; Mika Gissler; Tom Grotmol; Laura Madanat-Harjuoja; Anne Gulbech Ording; Olof Stephansson; Britton Trabert; Steinar Tretli; Rebecca Troisi; Henrik Toft Sørensen; Ingrid Glimelius
Journal:  Int J Cancer       Date:  2018-07-10       Impact factor: 7.396

4.  Ovarian Cancer in Women of African Ancestry (OCWAA) consortium: a resource of harmonized data from eight epidemiologic studies of African American and white women.

Authors:  Joellen M Schildkraut; Lauren C Peres; Traci N Bethea; Fabian Camacho; Deanna Chyn; Emily K Cloyd; Elisa V Bandera; Alicia Beeghly-Fadiel; Loren Lipworth; Charlotte E Joslin; Faith G Davis; Patricia G Moorman; Evan Myers; Heather M Ochs-Balcom; Veronica Wendy Setiawan; Malcolm C Pike; Anna H Wu; Lynn Rosenberg
Journal:  Cancer Causes Control       Date:  2019-06-24       Impact factor: 2.506

5.  Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.

Authors:  T Huang; S S Tworoger; W C Willett; M J Stampfer; B A Rosner
Journal:  Ann Oncol       Date:  2019-02-01       Impact factor: 32.976

6.  Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations.

Authors:  Britton Trabert; Tim Waterboer; Annika Idahl; Nicole Brenner; Louise A Brinton; Julia Butt; Sally B Coburn; Patricia Hartge; Katrin Hufnagel; Federica Inturrisi; Jolanta Lissowska; Alexander Mentzer; Beata Peplonska; Mark E Sherman; Gillian S Wills; Sarah C Woodhall; Michael Pawlita; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

Review 7.  Ovarian Cancer Prevention in High-risk Women.

Authors:  Sarah M Temkin; Jennifer Bergstrom; Goli Samimi; Lori Minasian
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

Review 8.  Association between dietary intake and risk of ovarian cancer: a systematic review and meta-analysis.

Authors:  Alireza Khodavandi; Fahimeh Alizadeh; Ahmad Faizal Abdull Razis
Journal:  Eur J Nutr       Date:  2020-07-13       Impact factor: 5.614

9.  Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies.

Authors:  Francesmary Modugno; Zhuxuan Fu; Susan J Jordan; Aocs Group; Jenny Chang-Claude; Renée T Fortner; Marc T Goodman; Kirsten B Moysich; Joellen M Schildkraut; Andrew Berchuck; Elisa V Bandera; Bo Qin; Rebecca Sutphen; John R McLaughlin; Usha Menon; Susan J Ramus; Simon A Gayther; Aleksandra Gentry-Maharaj; Chloe Karpinskyj; Celeste L Pearce; Anna H Wu; Harvey A Risch; Penelope M Webb
Journal:  Eur J Epidemiol       Date:  2020-09-21       Impact factor: 8.082

10.  Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women's Health Initiative Observational Study.

Authors:  Britton Trabert; Sally B Coburn; Roni T Falk; JoAnn E Manson; Louise A Brinton; Margery L Gass; Lewis H Kuller; Thomas E Rohan; Ruth M Pfeiffer; Lihong Qi; Marcia L Stefanick; Nicolas Wentzensen; Garnet L Anderson; Xia Xu
Journal:  Cancer Causes Control       Date:  2019-09-21       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.